A single injection has cured syphilis for eighty years, yet congenital syphilis rates have risen more than 200% in five years. A national penicillin shortage, no substitute drug for pregnant patients, and gaps in surveillance explain why.
Two FDA advisory committees faced imperfect evidence for two drugs in the same week and split in opposite directions. The deciding factor wasn't how much proof each had, but whether the proof could be believed.
The American Diabetes Association defended a journal's editorial independence in 2015 when it was cheap. In 2026 it suppressed its own researchers when defending them risked its NIH funding relationship.
The FDA paused all of Sarepta's LGMD gene-therapy trials after deaths tied to a shared viral vector, then restored access disease by disease. The pattern looks inconsistent but reflects a real difference in how safety and benefit evidence behave.
Novo's ziltivekimab hit its inflammation targets precisely in a 6,300-patient trial but produced no reduction in heart attacks, strokes, or cardiovascular deaths. The gap between a moved surrogate and an unmoved outcome is the whole lesson.
ICE Mortgage Technology returned to profitability and argued its data and workflow, not its models, are what AI cannot replicate. The bet is stronger in regulated mortgage than in most industries, but it is still a bet.
Second-lien and HELOC securitization is on pace for $41 billion in 2026, the most since the financial crisis. The record issuance isn't just a symptom of demand, it's the engine that distributes subordinate mortgage risk to bond investors.
FHFA data shows GSE loan modifications rising while forbearance and payment deferrals fall, just ahead of a policy shift to shorter forbearance windows. The tool mix is itself a diagnosis of borrower distress.
A survey found AI is now the top compliance concern for 85% of investment advisory firms, versus 37% for cybersecurity. The gap measures how unsettled AI's rules are, not how dangerous AI is compared with hackers.
Federal agencies say essential disease monitoring remains intact. Specialists warn that reduced staffing could make emerging threats harder to detect.
Read the ArticleEvery article on Mavengity is written by a dedicated topic desk and checked against current market practice.
Home, auto, life, and health coverage, explained clearly and checked against the fine print.
Browse InsuranceRates, refinancing, and first-time buyer strategy, without the jargon lenders assume you already know.
Browse MortgageBudgeting, saving, and everyday money habits that compound. No get-rich-quick promises.
Browse Personal FinanceContracts, consumer rights, and disputes, explained so you know where you stand.
Browse LegalHealth coverage and medical billing, broken down so surprise bills are less likely to surprise you.
Browse HealthcareWe start from public rate filings, regulator guidance, and lender disclosures, not marketing copy.
If a term needs a footnote, we explain it in the sentence instead of hiding it in the fine print.
We flag trade-offs and blind spots, not just the upside, so you get the full picture before you decide.
Mavengity is reader-supported and editorially independent from the products we cover.